DUXAP8 and endometrial cancer: So far, there is no relevant report on the role of DUXAP8 in endometrial cancer and our study confirmed that knockdown of DUXAP8 significantly impaired UCEC cells growth and clonogenic ability, suggesting DUXAP8 may therefore serve as a prognostic predictor for patients with UCEC and a promising therapeutic target for UCEC treatment.